CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 90 enrolled
Drug / intervention
3% Benzoyl Peroxide +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02052752
NCT02052752Phase 4Completed

A Randomized, Double-blinded Study to Evaluate the Ability of an Acne Treatment Product to Produce Visible Improvements in Acne Lesions Over a 5 Day Period of Once-daily Use

GlaxoSmithKline·interventional·Posted Feb 3, 2014·Updated May 18, 2015

In Brief

A Phase 4 clinical trial evaluating 3% Benzoyl Peroxide, 3% Benzoyl Peroxide Placebo, and 1 other intervention for Skin Diseases. Completed, enrolled 90 participants across 1 site.

Detailed Summary

5 Day study to assess how quickly a topical acne product begins to work.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSkin Diseases
CountriesUnited States
Collaborators--

Timeline

Phase 4CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedFeb 3, 2014
Enrollment StartFeb 1, 2014
Primary CompletionMay 1, 2014
TodayJul 2, 2026
Enrollment to primary: 3 monthsPosted 12.4 years ago

Interventions

3% Benzoyl Peroxidedrug

Test product contained 3% benzoyl peroxide in the form of a gel. It was applied on participant's face once-daily at approximately the same time on Days 0, 1, 2 and 3.

3% Benzoyl Peroxide Placebodrug

The vehicle gel was similar to the test product except that it did not contain 3% benzoyl peroxide. The vehicle gel served as the negative control and was applied on participant's face once-daily at approximately the same time on Days 0, 1, 2 and 3.

Neutrogena Rapid Clear®drug

A commercial product containing 2% salicylic acid that reportedly improves acne lesions was applied on participant's face once-daily at approximately the same time on Days 0, 1, 2 and 3.